In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B

Cancer Letters

Volumn 370, Issue 2, 2016, Pages 185-197

  Qazzaz, Mohannad E ^a   Raja, Vijay J ^a   Lim, Kuan Hon ^b   Kam, Toh Seok ^c   Lee, Jong Bong ^a   Gershkovich, Pavel ^a   Bradshaw, Tracey D ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM MALAYSIA CAMPUS   (Malaysia)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Apoptosis; Cell cycle; Natural products; PLK1; Reactive oxygen species; Tubulin

Indexed keywords

ANTINEOPLASTIC ALKALOID; CASPASE 3; CASPASE 7; JERANTININE B; JERANTININE B ACETATE; LIPOCORTIN 5; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; INDOLE ALKALOID; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL LINE; CANCER RESISTANCE; CELL POPULATION; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ISOLATION; DRUG SCREENING; ELIMINATION HALF-LIFE; ENZYME ACTIVATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HEPATIC CLEARANCE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RENAL CLEARANCE; TUBULIN POLYMERIZATION ASSAY; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CYTOSKELETON; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYTOSKELETON; HUMANS; INDOLE ALKALOIDS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; VINCRISTINE;

EID: 84949514050     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.10.013     Document Type: Article

References (55)

1. Teiten M.H., Gaascht F., Dicato M., Diederich M. Anticancer bioactivity of compounds from medicinal plants used in European medieval traditions. Biochem. Pharmacol 2013, 86:1239-1247.
2. von Schwarzenberg K., Vollmar A.M. Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett 2013, 332:295-303.
3. Dhami N. Trends in pharmacognosy: a modern science of natural medicines. J. Herb. Med 2013, 3:123-131.
4. Phillipson J.D. Phytochemistry and medicinal plants. Phytochemistry 2001, 56:237-243.
5. Mohan R., Katrukha E.A., Doodhi H., Smal I., Meijering E., Kapitein L.C., et al. End-binding proteins sensitize microtubules to the action of microtubule-targeting agents. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:8900-8905.
6. Zhou J., Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 2005, 5:65-71.
7. Stanton R.A., Gernert K.M., Nettles J.H., Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med. Res. Rev 2011, 31:443-481.
8. Raja V.J., Lim K.H., Leong C.O., Kam T.S., Bradshaw T.D. Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules. Invest. New Drugs 2014, 32:838-850.
9. Diaz-Moralli S., Tarrado-Castellarnau M., Miranda A., Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther 2013, 138:255-271.
10. Hartwell L.H., Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246:629-634.
11. Ling Y.H., Consoli U., Tornos C., Andreeff M., Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int. J. Cancer 1998, 75:925-932.
12. Tu Y., Cheng S., Zhang S., Sun H., Xu Z. Vincristine induces cell cycle arrest and apoptosis in SH-SY5Y human neuroblastoma cells. Int. J. Mol. Med 2013, 31:113-119.
13. Lim K.H., Hiraku O., Komiyama K., Kam T.S. Jerantinines A-G, cytotoxic Aspidosperma alkaloids from Tabernaemontana corymbosa. J. Nat. Prod 2008, 71:1591-1594.
14. Frei R., Staedler D., Raja A., Franke R., Sasse F., Gerber-Lemaire S., et al. Total synthesis and biological evaluation of jerantinine E. Angew. Chem. Int. Ed. Engl 2013, 52:13373-13376.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
16. Morgan D.M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol. Biol 1998, 79:179-183.
17. Munshi A., Hobbs M., Meyn R.E. Clonogenic cell survival assay. Methods Mol. Med 2005, 110:21-28.
18. Plumb J.A. Cell sensitivity assays: clonogenic assay. Methods Mol. Med 2004, 88:159-164.
19. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 1991, 139:271-279.
20. Shelanski M.L., Gaskin F., Cantor C.R. Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. U.S.A. 1973, 70:765-768.
21. Lee J.C., Timasheff S.N. In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry 1977, 16:1754-1764.
22. Lam F., Bradshaw T.D., Mao H., Roberts S., Pan Y., Wang S. ZJU-6, a novel derivative of erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities. Invest. New Drugs 2012, 30:1899-1907.
23. Chen R., Keating M.J., Gandhi V., Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005, 106:2513-2519.
24. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 1976, 72:248-254.
25. Collins H.M., Abdelghany M.K., Messmer M., Yue B., Deeves S.E., Kindle K.B., et al. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer 2013, 13:37.
26. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jarvinen T., et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov 2008, 7:255-270.
27. Blajeski A.L., Phan V.A., Kottke T.J., Kaufmann S.H. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J. Clin. Invest 2002, 110:91-99.
28. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
29. Gonzalez-Cid M., Cuello M.T., Larripa I. Comparison of the aneugenic effect of vinorelbine and vincristine in cultured human lymphocytes. Mutagenesis 1999, 14:63-66.
30. Kartner N., Riordan J.R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221:1285-1288.
31. Ikezoe T., Yang J., Nishioka C., Takezaki Y., Tasaka T., Togitani K., et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009, 23:1564-1576.
32. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
33. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5789-5794.
34. Degenhardt Y., Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin. Cancer Res 2010, 16:384-389.
35. Rudolph D., Baum A. In vivo efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in human hematopoietic cancers. EJC Suppl 2007, 5:111.
36. Triscott J., Lee C., Foster C., Manoranjan B., Pambid M.R., Berns R., et al. Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children. Cancer Res 2013, 73:6734-6744.
37. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov 2013, 12:931-947.
38. Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012, 2012:137289.
39. Groninger E., Meeuwsen-De Boer G.J., De Graaf S.S., Kamps W.A., De Bont E.S. Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?. Int. J. Oncol 2002, 21:1339-1345.
40. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011, 71:1385-1396.
41. Simon H.U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418.
42. Le Grand M., Rovini A., Bourgarel-Rey V., Honore S., Bastonero S., Braguer D., et al. ROS-mediated EB1 phosphorylation through Akt/GSK3beta pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget 2014, 5:3408-3423.
43. Hsu M.H., Liu C.Y., Lin C.M., Chen Y.J., Chen C.J., Lin Y.F., et al. 2-(3-Methoxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (HKL-1) induces G2/M arrest and mitotic catastrophe in human leukemia HL-60 cells. Toxicol. Appl. Pharmacol 2012, 259:219-226.
44. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
45. Janicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem 1998, 273:9357-9360.
46. Jiang W., Kim S., Zhang X., Lionberger R.A., Davit B.M., Conner D.P., et al. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int. J. Pharm 2011, 418:151-160.
47. Hamalainen M.D., Frostell-Karlsson A. Predicting the intestinal absorption potential of hits and leads. Drug Discov. Today Technol 2004, 1:397-405.
48. De Buck S.S., Sinha V.K., Fenu L.A., Nijsen M.J., Mackie C.E., Gilissen R.A. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos 2007, 35:1766-1780.
49. Mathias N.R., Crison J. The use of modeling tools to drive efficient oral product design. AAPS J. 2012, 14:591-600.
50. Heikkinen A.T., Baneyx G., Caruso A., Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus (TM). Eur. J. Pharm. Sci 2012, 47:375-386.
51. Parrott N., Jones H., Paquereau N., Lave T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol 2005, 96:193-196.
52. Kocic I., Homsek I., Dacevic M., Grbic S., Parojcic J., Vucicevic K., et al. A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets. Biopharm. Drug Dispos 2012, 33:146-159.
53. Parrott N., Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm 2008, 5:760-775.
54. Sinha V.K., Snoeys J., Osselaer N.V., Peer A.V., Mackie C., Heald D. From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm. Drug Dispos 2012, 33:111-121.
55. Hosea N.A., Jones H.M. Predicting pharmacokinetic profiles using in silico derived parameters. Mol. Pharm 2013, 10:1207-1215.